for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Kodiak Sciences Inc

KOD.OQ

Latest Trade

83.97USD

Change

1.15(+1.39%)

Volume

49,116

Today's Range

82.88

 - 

85.78

52 Week Range

45.04

 - 

170.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
82.82
Open
82.88
Volume
49,116
3M AVG Volume
7.40
Today's High
85.78
Today's Low
82.88
52 Week High
170.98
52 Week Low
45.04
Shares Out (MIL)
51.26
Market Cap (MIL)
4,245.77
Forward P/E
-18.00
Dividend (Yield %)
--

Next Event

Q2 2021 Kodiak Sciences Inc Earnings Release

Latest Developments

More

Kodiak Sciences Reports Q4 Loss Per Share $0.97

Kodiak Sciences Announces Pricing Of $560.9 Mln Public Offering Of Common Stock

Kodiak Sciences Announces Proposed Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Kodiak Sciences Inc

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy.

Industry

Biotechnology & Drugs

Contact Info

1200 PAGE MILL RD

PALO ALTO, CA

94304

United States

+1.650.2810850

https://kodiak.com/

Executive Leadership

Victor Perlroth

Chairman of the Board, President, Chief Executive Officer

John A. Borgeson

Chief Financial Officer, Senior Vice President, Secretary

Jason Ehrlich

Chief Medical Officer and Chief Development Officer

Robert A. Profusek

Lead Independent Director

Felix J. Baker

Independent Director

Key Stats

2.50 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.400

2019

-1.250

2020

-2.910

2021(E)

-4.602
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-22.31
Return on Equity (TTM)
-21.57

Latest News

Latest News

BRIEF-Kodiak Sciences Announces New Longer-Term Safety, Efficacy And Durability Data From Ongoing Phase 1B Study Of KSI-301

* KODIAK SCIENCES INC - ANNOUNCES NEW LONGER-TERM SAFETY, EFFICACY AND DURABILITY DATA FROM ONGOING PHASE 1B STUDY OF KSI-301

BRIEF-Kodiak Sciences Announces Q1 2020 Financial Results

* KODIAK SCIENCES ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

BRIEF-Kodiak Sciences Increases Board Size To 7, Appoints Charles Bancroft To Fill Vacant Board Seat

* KODIAK SCIENCES INC - INCREASED BOARD SIZE FROM 6 TO 7 MEMBERS AND APPOINTED CHARLES BANCROFT TO FILL VACANT BOARD SEAT Source : (https://bit.ly/3bLNhtX) Further company coverage:

BRIEF-Kodiak Sciences Appoints Charles Bancroft To Board Of Directors

* KODIAK SCIENCES APPOINTS CHARLES BANCROFT TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-"Kodiak" And "Kodiak Sciences" Trademarks Registered To Kodiak Sciences Inc. For Its Exclusive Use

* "KODIAK" AND "KODIAK SCIENCES" TRADEMARKS REGISTERED TO KODIAK SCIENCES INC. FOR ITS EXCLUSIVE USE Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up